Great Point Partners LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Great Point Partners LLC disclosed 31 US equity positions worth $184.0m in its Q1 2025 13F filing. The largest position was CYTK at 8.1% of the reported book, followed by 4XC1 and EOLS. Against the Q4 2024 filing, it opened 9 new positions, added to 6 and reduced 8 among the top 31 holdings.
What did Great Point Partners LLC own in Q1 2025? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | CYTK CYTOKINETICS INC | Healthcare | 8.1% | $14.9m | 370,000 | 3% | added |
| 2 | 4XC1 KALVISTA PHARMACEUTICALS INC | 6.4% | $11.7m | 1,014,367 | -43% | reduced | |
| 3 | EOLS EVOLUS INC | Healthcare | 6.2% | $11.4m | 944,743 | 5% | added |
| 4 | ABVX ABIVAX SA | 5.6% | $10.2m | 1,638,111 | -1% | reduced | |
| 5 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 5.5% | $10.1m | 750,000 | 0% | held |
| 6 | MERUS N V | 5.4% | $10.0m | 237,156 | 50% | added | |
| 7 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 5.2% | $9.5m | 4,973,840 | – | new |
| 8 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.5% | $8.2m | 245,272 | 0% | held |
| 9 | ASND ASCENDIS PHARMA A/S | Healthcare | 4.2% | $7.8m | 50,000 | – | new |
| 10 | DVAX DYNAVAX TECHNOLOGIES CORP | 4.2% | $7.7m | 595,879 | -31% | reduced | |
| 11 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 4.1% | $7.5m | 250,000 | -50% | reduced |
| 12 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 3.5% | $6.4m | 1,811,996 | – | new |
| 13 | IMVT IMMUNOVANT INC | Healthcare | 3.5% | $6.4m | 375,000 | – | new |
| 14 | UNCY UNICYCIVE THERAPEUTICS INC | 3.4% | $6.3m | 10,980,000 | 0% | held | |
| 15 | NGNE NEUROGENE INC | 3.0% | $5.5m | 470,964 | 6% | added | |
| 16 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.7% | $5.0m | 275,000 | 0% | held |
| 17 | LEGN LEGEND BIOTECH CORP | Healthcare | 2.5% | $4.7m | 138,240 | – | new |
| 18 | PCVX VAXCYTE INC | Healthcare | 2.4% | $4.4m | 115,517 | – | new |
| 19 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 2.3% | $4.2m | 2,728,910 | -9% | reduced |
| 20 | HELIX ACQUISITION CORP II | 2.3% | $4.2m | 373,833 | -25% | reduced | |
| 21 | ZURA ZURA BIO LTD | Healthcare | 2.2% | $4.1m | 3,170,194 | 0% | held |
| 22 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.9% | $3.4m | 175,562 | – | new |
| 23 | ACLXGBX ARCELLX INC | 1.6% | $3.0m | 45,000 | – | new | |
| 24 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 1.6% | $2.9m | 1,275,000 | 11% | added |
| 25 | CNTX CONTEXT THERAPEUTICS INC | 1.6% | $2.9m | 4,683,711 | 0% | held | |
| 26 | RZLT REZOLUTE INC | 1.3% | $2.4m | 833,042 | 34% | added | |
| 27 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.2% | $2.2m | 149,702 | – | new | |
| 28 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 1.2% | $2.1m | 626,275 | -24% | reduced |
| 29 | PROMIS NEUROSCIENCES INC | 1.0% | $1.8m | 2,645,128 | 0% | held | |
| 30 | UPB UPSTREAM BIO INC | 1.0% | $1.8m | 300,000 | 0% | held | |
| 31 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.6% | $1.1m | 850,000 | -19% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.